News
The international president of Eli Lilly stated that the company is studying the new fast-track review process of the U.S. Food and Drug Administration, but it cannot assume that its new weight loss drug will be approved in this manner
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments